Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• ReedKBBrewerJDLohseCMBringeKEPruittCNGibsonLEIncreasing incidence of melanoma among young adults: an epidemiologic study in Olmsted County, MinnesotaMayo Clin Proc201287432833422469345
   PubMed Web of Science ®Google Scholar
• GuyGPEkwuemeDUYears of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literaturePharmacoeconomics2011291086387421846158
   PubMed Web of Science ®Google Scholar
• BalchCMGershenwaldJESoongSJFinal version of 2009 AJCC melanoma staging and classificationJ Clin Oncol200927366199620619917835
   PubMed Web of Science ®Google Scholar
• LeghaSSThe role of interferon alfa in the treatment of metastatic melanomaSemin Oncol1997241 Suppl 4S24S319122731
   PubMed Web of Science ®Google Scholar
• MocellinSPasqualiSRossiCRNittiDInterferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysisJ Natl Cancer Inst2010102749350120179267
   PubMed Web of Science ®Google Scholar
• KirkwoodJMStrawdermanMHErnstoffMSSmithTJBordenECBlumRHInterferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684J Clin Oncol19961417178558223
   PubMed Web of Science ®Google Scholar
• JonaschEKumarUNLinetteGPAdjuvant high-dose interferon alfa-2b in patients with high-risk melanomaCancer J20006313914510882328
   PubMed Web of Science ®Google Scholar
• McMastersKMEdwardsMJRossMIUlceration as a predictive marker for response to adjuvant interferon therapy in melanomaAnn Surg2010252346046520739846
   PubMed Web of Science ®Google Scholar
• EggermontASuciuSTestoriAUlceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991Eur J Cancer201248221822522056637
   PubMed Web of Science ®Google Scholar
• GogasHIoannovichJDafniUPrognostic significance of autoimmunity during treatment of melanoma with interferonN Engl J Med2006354770971816481638
   PubMed Web of Science ®Google Scholar
• SullivanRJFlahertyKTBRAF in melanoma: pathogenesis, diagnosis, inhibition, and resistanceJ Skin Cancer2011201142323922175026
   PubMedGoogle Scholar
• AtkinsMBLotzeMTDutcherJPHigh-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol19991772105211610561265
   PubMed Web of Science ®Google Scholar
• SchwartzRNStoverLDutcherJManaging toxicities of high-dose interleukin-2Oncology (Williston Park)20021611 Suppl 13112012469935
   PubMed Web of Science ®Google Scholar
• PetrellaTQuirtIVermaSSingle-agent interleukin-2 in the treatment of metastatic melanomaCurr Oncol2007141212617576460
   PubMedGoogle Scholar
• JosephRWSullivanRJHarrellRCorrelation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaJ Immunother2012351667222130161
   PubMed Web of Science ®Google Scholar
• SullivanRJHoshidaYBrunetJA single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of responseJ Clin Oncol200927Suppl 15 Abstr 9003
   Web of Science ®Google Scholar
• RosenbergSYangJSchwartzentruberDProspective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2bJ Clin Oncol199917396897510071291
   PubMed Web of Science ®Google Scholar
• SabatinoMKim-SchulzeSPanelliMCSerum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapyJ Clin Oncol200927162645265219364969
   PubMed Web of Science ®Google Scholar
• AtkinsMBMierJWParkinsonDRGouldJABerkmanEMKaplanMMHypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cellsN Engl J Med198831824155715633259674
   PubMed Web of Science ®Google Scholar
• WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol201011215516420004617
   PubMed Web of Science ®Google Scholar
• O’DaySJMaioMChiarion-SileniVEfficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnn Oncol20102181712171720147741
   PubMed Web of Science ®Google Scholar
• WeberJSKählerKCHauschildAManagement of immune-related adverse events and kinetics of response with ipilimumabJ Clin Oncol201230212691269722614989
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011365262517252621639810
   PubMed Web of Science ®Google Scholar
• LebbeCWeberJMaioBLong-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trialsJ Clin Oncol201331Suppl 15 Abstr 9053
   Google Scholar
• MargolinKErnstoffMSHamidOIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialLancet Oncol201213545946522456429
   PubMed Web of Science ®Google Scholar
• RobertCSchadendorfDMessinaMHodiFSO’DaySMDX010-20 InvestigatorsEfficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease controlClin Cancer Res20131982232223923444228
   PubMed Web of Science ®Google Scholar
• Di GiacomoAMBiagioliMMaioMThe emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indicationsSemin Oncol201037549950721074065
   PubMed Web of Science ®Google Scholar
• BermanDParkerSMSiegelJBlockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanomaCancer Immun2010101121090563
   PubMedGoogle Scholar
• TorinoFBarnabeiADe VecchisLSalvatoriRCorselloSMHypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare diseaseOncologist201217452553522477725
   PubMed Web of Science ®Google Scholar
• USFoodDrug AdministrationYervoy (ipilimumab): risk evaluation and mitigation strategy (REMS) – severe immune-mediated adverse reactions2011 Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm249770.htmAccessed February 21, 2013
   Google Scholar
• WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295
   PubMed Web of Science ®Google Scholar
• HalesRKBanchereauJRibasAAssessing oncologic benefit in clinical trials of immunotherapy agentsAnn Oncol201021101944195120237004
   PubMed Web of Science ®Google Scholar
• KuGYYuanJPageDBSingle-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survivalCancer201011671767177520143434
   PubMed Web of Science ®Google Scholar
• BermanDMWolchokJWeberJAssociation of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumabJ Clin Oncol200927Suppl 15 Abstr 3020
   Web of Science ®Google Scholar
• HamidOChasalowSDTsuchihashiZAssociation of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumabJ Clin Oncol200927Suppl 15 Abstr 9008
   Web of Science ®Google Scholar
• RubinsteinJCSznolMPavlickACIncidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032J Transl Med201086720630094
   PubMed Web of Science ®Google Scholar
• BrissySGaudy-MarquesteCMalletSBRAF mutation as a pejorative marker in metastatic melanomaJ Clin Oncol201230Suppl Abstr 8555
   Google Scholar
• ChapmanPBHauschildARobertCfor the BRIM-3 Study GroupImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• GummadiTDroncaRSKimCImpact of BRAF mutation and effectiveness of BRAF inhibitor on the brain metastases in patients with metastatic melanomaJ Clin Oncol20133115 Suppl Abstr 9048
   Web of Science ®Google Scholar
• LarkinJMQueiroloPAranceAMAn open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanomaJ Clin Oncol201230Suppl Abstr 8517
   Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol20082667770418173375
   PubMed Web of Science ®Google Scholar
• HiranoFKanekoKTamuraHBlockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunityCancer Res20056531089109615705911
   PubMed Web of Science ®Google Scholar
• GhiottoMGauthierLSerriariNPD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1Int Immunol201022865166020587542
   PubMed Web of Science ®Google Scholar
• PatnaikAKangSPTolcherAWPhase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumorsJ Clin Oncol201230Suppl Abstr 2512
   PubMedGoogle Scholar
• BrahmerJRDrakeCGWollnerIPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJ Clin Oncol201028193167317520516446
   PubMed Web of Science ®Google Scholar
• SznolMKlugerHHodiFSurvival and long-term follow up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-Pd-1; BMS-936558; ONO-4538)J Clin Oncol201331Suppl 15 Abstr 9006
   Google Scholar
• RibasARobertCDaudAClinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanomaJ Clin Oncol201331Suppl 15Abstr 9010
   Web of Science ®Google Scholar
• Business WireMerck presents early-stage interim data for MK-3475, an investigational therapy for the treatment of advanced melanoma phase II study being initiated [press release]Whitehouse StationNJ, USA11112012 Available from: http://www.businesswire.com/news/home/20121111005025/en/Merck-Presents-Early-Stage-Interim-Data-MK-3475-Investigational#.U3FPcvmSxhoAccessed May 13, 2014
   Google Scholar
• SznolMPowderlyJDSmithDCSafety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignanciesJ Clin Oncol201028Suppl 15 Abstr 2506
   Web of Science ®Google Scholar
• HamidOSosmanJALawrenceDPClinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanomaJ Clin Oncol201331Suppl 15 Abstr 9010
   Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• GrossoJHorakCInzunzaDAssociation of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD1; BMS-936558; ONO-4538)J Clin Oncol201331Suppl 15 Abstr 3016
   Web of Science ®Google Scholar
• RibasAHerseyPMiddletonMRNew challenges in endpoints for drug development in advanced melanomaClin Cancer Res201218233634122142824
   PubMed Web of Science ®Google Scholar
• PostowMACallahanMKBarkerCAImmunologic correlates of the abscopal effect in a patient with melanomaN Engl J Med20123661092593122397654
   PubMed Web of Science ®Google Scholar
• PrietoPAYangJCSherryRMCTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanomaClin Cancer Res20121872039204722271879
   PubMed Web of Science ®Google Scholar
• KuchadkarRRGibneyGTWeberJA phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanomaJ Clin Oncol201331Suppl 15 Abstr 9079
   Web of Science ®Google Scholar
• RibasAHodiSCallahanMHepatotoxicity with combination of vemurafenib and ipilimumabN Engl J Med2013368141365136623550685
   PubMed Web of Science ®Google Scholar
• WolchokJKlugerHCallahanMSafety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients with advanced melanomaJ Clin Oncol201331Suppl 15 Abstr 9012
   Web of Science ®Google Scholar
• HodiFSLeeSJMcDermottDFMulticenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608J Clin Oncol201331Suppl 15 Abstr CRA9007
   Google Scholar
• GarberKBeyond ipilimumab: new approaches target the immunological synapseJ Natl Cancer Inst2011103141079108221737695
   PubMedGoogle Scholar
• InfanteJRFalchookGSLawrenceDPPhase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)J Clin Oncol201129Suppl Abstr 8503
   Google Scholar
• SosmanJDaudAWeberJBRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naïve and BRAFi-resistant patients with BRAF mutation-positive metastatic melanomaJ Clin Oncol201331Suppl 15 Abstr 9005
   Web of Science ®Google Scholar
• AckermanAMcDermottDFLawrenceLPOutcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenibJ Clin Oncol201230Suppl Abstr 8569
   Google Scholar
• AsciertoPASimeoneEGiannarelliDGrimaldiAMRomanoAMozzilloNSequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical useJ Transl Med20121010722640478
   PubMed Web of Science ®Google Scholar
• GajewskiTFFuertesMSpaapenRZhengYKlineJMolecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironmentCurr Opin Immunol201123228629221185705
   PubMed Web of Science ®Google Scholar